Dragonfly’s trinkets

Dragonfly Therapeutics Inc. is developing trispecific antibodies that direct endogenous NK cells toward tumor cells. By targeting two distinct activating receptors on NK cells, plus a tumor antigen, the antibodies could be more potent than competing bispecifics that target only one NK cell receptor.

NK cells are part of the innate immune system and target stressed or abnormal cells, including tumor cells, so long as they meet two criteria: they express NK cell-activating ligands and lack NK cell-inhibiting major histocompatibility complex (MHC) class I molecules...